CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 39 enrolled
Drug / intervention
V920 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02269423
NCT02269423Phase 1Completed
CompareCT.gov

A Phase 1 Randomized, Single-Center, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects

Merck Sharp & Dohme LLC·interventional·Posted Oct 21, 2014·Updated Oct 23, 2019

In Brief

A Phase 1 clinical trial evaluating V920 and Placebo for Ebola Virus. Completed, enrolled 39 participants.

Detailed Summary

This is a study of the anti-Ebola vaccine vesicular stomatitis virus (VSV) ZEBOV (Zaire ebolavirus) also known as V920 and BPSC-1001. The purpose of this study is to test how safe the vaccine is in humans and how well it makes the human immune system cause an immune- or defense-response to Ebola virus. This vaccine will be studied at different doses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEbola Virus
Countries--
CollaboratorsBioProtection Systems Corporation, United States Department of Defense

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 21, 2014
Enrollment StartOct 13, 2014
Primary CompletionAug 25, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.7 years ago

Interventions

V920biological

Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.

Placeboother

Normal saline placebo.